      Document 0008
 DOCN  DRG0008
 UNIQUE IDENTIFIER        DRG-0239
 NAME OF SUBSTANCE        Pneumococcal vaccine polyvalent ( 23-valent )
                          [NIAID ACTG 292]
 SYNONYMS                 PNU-IMUNE 23 [MMWR 1989 Feb 10;38(5)]
 PROTOCOL ID NUMBERS      NIAID ACTG 292
 SECONDARY SOURCE ID      DRG
 DISEASES STUDIED/TREATED HIV-associated pneumococcal disease [NIAID
                          ACTG 292]
 CLASSIFICATION CODE      Vaccine [NIAID ACTG 292]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Purified capsular
                          polysaccharide antigens of 23 types of
                          Streptococcus pneumoniae [MMWR 1989 Feb
                          10;38(5)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: (Danish types 1, 2, 3, 4,
                          5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,
                          17F, 18C, 19F, 19A, 20, 22F, 23F, 33F). [MMWR
                          1989 Feb 10;38(5)]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Intramuscular or
                          subcutaneous. [NIAID ACTG 292]
 SUBSTANCE DELIVERY DATA  STORAGE INSTRUCTIONS: Store at 2-8 C (35-46
                          F). Do not freeze. [NIAID ACTG 292]
 MANUFACTURERS            Lederle - Praxis Biologicals
 REFERENCES               Ahmed F, Steinhoff MC, Rodriguez-Barradas MC,
                          Hamilton RG, Musher DM, Nelson KE. Effect of
                          human immunodeficiency virus type 1 infection
                          on the antibody response to a glycoprotein
                          conjugate pneumococcal vaccine: results from
                          a randomized trial. J Infect Dis. 1996
                          Jan;173(1):83-90.
 REFERENCES               Loeliger AE, Rijkers GT, Aerts P, Been-Tiktak
                          A, Hoepelman AI, van Kijk H, Borleffs JC.
                          Deficient antipneumococcal polysaccharide
                          responses in HIV-seropositive patients. FEMS
                          Immunol Med Microbiol. 1995 Sep;12(1):33-41.
 REFERENCES               Keller DW, Breiman RF. Preventing bacterial
                          respiratory tract infections among persons
                          infected with human immunodeficiency virus.
                          Clin Infect Dis. 1995 Aug;21 Suppl 1:S77-83.
 REFERENCES               Sanders LA, Rijkers GT, Kuis W,
                          Tenbergen-Meekes AJ, de Graeff-Meeder BR,
                          Hiemstra I, Zegers BJ. Defective
                          antipneumococcal polysaccharide antibody
                          response in children with recurrent
                          respiratory tract infections. J Allergy Clin
                          Immunol. 1993 Jan;91(1 Pt 1):110-9.
 REFERENCES               Rodriguez-Barradas MC, Musher DM, Lahart C,
                          Lacke C, Groover J, Watson D, Baughn R, Cate
                          T, Crofoot G. Antibody to capsular
                          polysaccharides of Streptococcus pneumoniae
                          after vaccination of human immunodeficiency
                          virus-infected subjects with 23-valent
                          pneumococcal vaccine. J Infect Dis. 1992
                          Mar;165(3):553-6.
 REFERENCES               Lambert JS, Insel R, Weissbach N, Keefer MC,
                          Reid J, Anderson P. The immunogenicity of
                          streptococcus pneumoniae (Pn) conjugate
                          vaccines in patients with human
                          immunodeficiency virus (HIV) infection. Int
                          Conf AIDS. 1990 Jun 20-23;6(1):209 (abstract
                          no. Th.A.358).
 ENTRY MONTH              9601
 LAST REVISION DATE       042496
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
